Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued ...
Morgan Stanley lowered the firm’s price target on Goldman Sachs (GS) to $659 from $782 and keeps an Overweight rating on the shares. The robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback